Elutia (ELUT) Competitors $2.27 +0.19 (+9.13%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$2.28 +0.00 (+0.22%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. TERN, HUMA, PRTA, HRTX, AMRN, PRME, SNDL, AQST, CTOR, and OLMAShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), SNDL (SNDL), Aquestive Therapeutics (AQST), Citius Oncology (CTOR), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Its Competitors Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Aquestive Therapeutics Citius Oncology Olema Pharmaceuticals Terns Pharmaceuticals (NASDAQ:TERN) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Does the media refer more to TERN or ELUT? In the previous week, Terns Pharmaceuticals had 1 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Terns Pharmaceuticals and 2 mentions for Elutia. Elutia's average media sentiment score of 0.30 beat Terns Pharmaceuticals' score of -0.50 indicating that Elutia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Elutia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer TERN or ELUT? Terns Pharmaceuticals currently has a consensus price target of $15.63, suggesting a potential upside of 244.92%. Elutia has a consensus price target of $8.00, suggesting a potential upside of 252.42%. Given Elutia's stronger consensus rating and higher possible upside, analysts clearly believe Elutia is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TERN or ELUT more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Elutia's net margin of -168.23%. Elutia's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -28.81% -27.55% Elutia -168.23%N/A -96.70% Which has more volatility and risk, TERN or ELUT? Terns Pharmaceuticals has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Do institutionals & insiders believe in TERN or ELUT? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, TERN or ELUT? Elutia has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.09-4.16Elutia$24.38M3.83-$53.95M-$1.93-1.18 SummaryElutia beats Terns Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.52M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-1.1820.8026.9720.11Price / Sales3.83286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book-1.737.487.985.56Net Income-$53.95M-$55.04M$3.16B$248.40M7 Day Performance5.09%2.44%2.36%4.67%1 Month Performance20.11%1.90%2.15%6.64%1 Year Performance-51.29%4.35%33.78%21.31% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.5801 of 5 stars$2.27+9.1%$8.00+252.4%-53.0%$85.52M$24.38M-1.18180TERNTerns Pharmaceuticals3.7045 of 5 stars$3.73-2.6%$15.63+318.9%-39.8%$334.50MN/A-3.4240HUMAHumacyte2.749 of 5 stars$2.09-1.4%$11.71+460.5%-54.7%$328.85M$1.57M-3.03150News CoverageGap UpPRTAProthena3.0445 of 5 stars$6.07-0.2%$31.50+418.9%-67.7%$327.27M$135.16M-2.92130HRTXHeron Therapeutics3.8245 of 5 stars$2.07-3.3%$5.00+141.5%-25.9%$326.49M$144.29M-34.50300Positive NewsAMRNAmarin0.6044 of 5 stars$16.22+3.2%$12.00-26.0%+13.8%$325.31M$228.61M-4.46360High Trading VolumePRMEPrime Medicine4.0534 of 5 stars$2.47+2.1%$10.08+308.2%-25.3%$324.30M$3.85M-1.20234Options VolumeHigh Trading VolumeSNDLSNDL3.513 of 5 stars$1.21-1.6%$3.63+199.6%-29.9%$323.21M$671.81M-4.172,516AQSTAquestive Therapeutics1.2446 of 5 stars$3.31+1.8%$10.14+206.4%+53.3%$322.82M$57.56M-5.61160CTORCitius Oncology0.3975 of 5 stars$4.35-3.3%$3.00-31.0%N/A$321.99MN/A0.00N/AOLMAOlema Pharmaceuticals1.726 of 5 stars$4.26-7.8%$24.50+475.1%-58.0%$316.11MN/A-2.1270Positive News Related Companies and Tools Related Companies TERN Competitors HUMA Competitors PRTA Competitors HRTX Competitors AMRN Competitors PRME Competitors SNDL Competitors AQST Competitors CTOR Competitors OLMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELUT Stock Alerts